Bio-Techne (NASDAQ: TECH) reported Q3 EPS of $1.21, $0.07 better than the analyst estimate of $1.14. Revenue for the quarter came in at $184.9 million versus the consensus estimate of $182.9 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.